A phase I/II, proof-of-concept trial of RX 3117 in patients with pancreatic cancer.

Trial Profile

A phase I/II, proof-of-concept trial of RX 3117 in patients with pancreatic cancer.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs Fluorocyclopentenylcytosine (Primary)
  • Indications Pancreatic cancer
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 11 Sep 2017 According to a Rexahn Pharmaceuticals media release, initial data readout from stage 2 of this trial is expected 4Q 2017.
    • 20 Jan 2017 According to Rexahn Pharmaceuticals media release, stage 2 of this trial is ongoing and an initial data readout is expected late in 2/3Q 2017.
    • 13 Sep 2016 According to a Rexahn Pharmaceuticals media release, stage 2 of this phase Ib/IIa trial was initiated in September 2016. Preliminary efficacy results from stage 1 of the study will be presented at the European Society for Medical Oncology (ESMO) conference, 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top